Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years
- PMID: 33847720
- DOI: 10.1001/jama.2021.0833
Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years
Comment in
-
Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years-Reply.JAMA. 2021 Apr 13;325(14):1471-1472. doi: 10.1001/jama.2021.0836. JAMA. 2021. PMID: 33847718 No abstract available.
Comment on
-
Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.JAMA. 2020 Dec 8;324(22):2324-2327. doi: 10.1001/jama.2020.19395. JAMA. 2020. PMID: 33289818 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
